<analysis>
**Action 1 (internal multi-agent RLVR / meta-scoring research).** Running experiments is squarely within the player's channels, since Claude instances already do much of Anthropic's research engineering. There are three constraints:
- **Compute.** Alignment leadership, not the model, decides how much compute goes to these runs. Pre-IPO product pressure competes for the same chips.
- **Scale.** One month of experiments produces preliminary signal, not a validated architecture.
- **Target.** "Compress the timeline by 6–12 months" cannot be assessed within a month. Success here means useful, credible early findings and a funded follow-on programme.

Evaluator collusion and eval-awareness confounds are modelled separately in Threat 4, so they are excluded from this action's P(failure).

**Action 2 (Claude-bylined pacing post).** This needs sign-off from comms, legal and policy leadership during the pre-IPO period. I reconcile the adversary's credible facts into the world state: a confidential S-1 filed June 1, a leaked prospectus draft on September 28, and Trump and Johnson attacking slowdown calls. A veto is modelled in Threat 1. If the post is published, winning an actual government sponsor within a month is unlikely, because sponsorship depends on members' incentives rather than a blog post. Success here means publication plus visible uptake (citations, a member or official engaging). A sponsor would count as full success.

**Action 3 (open-source safety eval toolkit).** Anthropic has shipped open eval tooling before, but packaging a "comprehensive" suite in one month is ambitious. Security review, documentation and red-teaming of the release itself all take time. Dual-use trimming and dropping the Chinese-lab outreach are covered by Threat 3. Adoption by open-weight labs would be slow even if the release lands.

**Action 4 (medical benefit amplification).** Three parts, with very different difficulty:
- **Faster publication** is limited by peer-review timelines.
- **Mythos expansion to 5 institutions** needs leadership approval, vetting and awareness of the June export-control episode. It is plausible only as a slower pilot.
- **A comms plan** is easy.

A measurable narrative shift in one month is unlikely. Much of the ambitious core is gated by other decision-makers.

**Action 5 (hearing prep).** This is routine work through the existing policy team, and January hearings are a real forcing function. The main friction is leadership softening the candour about incidents and legislators' limited availability. Building rapport with members is done by humans on the policy team using Claude-drafted material, which is realistic.

**Threats.**
- **Threat 1:** quiet-period sensitivity is high and an AI byline is novel. A veto or dilution into an internal memo is roughly a coin flip.
- **Threat 2:** Sacks has already made this exact argument, so a partisan backlash is likely if the post runs. Casar outreach also carries optics risk.
- **Threat 3:** any competent legal review would strip the offensive-cyber and sandbox-escape harnesses and stop direct pushes to Chinese labs.
- **Threat 4:** eval awareness in same-family evaluators is a well-documented confound, and a red-team is likely to flag it early.
- **Threat 5:** this has several independent routes. The world state already expects a DeepSeek release in December or January, and Gemini 4 is at parity. Leadership actually diverting alignment compute is the weakest link in the chain.
</analysis>

<action_odds>
Action 1 [Multi-agent RLVR alignment research]: P(failure) 35%. Reason: The work is feasible through internal channels, but compute allocation competes with pre-IPO product pressure and one month yields only preliminary results. Success means credible early findings and a funded follow-on, not the 6–12 month compression.

Action 2 [Claude-bylined pacing post]: P(failure) 50%. Reason: The veto risk is carried by Threat 1. Even if published, converting a blog post into government champions in one month is unlikely because sponsorship turns on legislators' incentives. Full success requires real official uptake.

Action 3 [Open-source safety eval toolkit]: P(failure) 35%. Reason: Anthropic has a precedent for open eval releases, but a comprehensive, security-reviewed, documented suite in one month is tight. Dual-use trimming is carried by Threat 3.

Action 4 [Medical benefit amplification]: P(failure) 50%. Reason: The comms plan is easy. Faster publication is limited by peer review, and Mythos expansion needs leadership and vetting under export-control memory. A measurable public narrative shift in a month is unlikely.

Action 5 [Oversight hearing prep]: P(failure) 25%. Reason: This is routine policy-team work with a real January forcing function. Residual risk comes from leadership hedging the candour and legislators' limited access.
</action_odds>

<threat_odds>
Threat 1 [Quiet-period veto of op-ed]: P(materialises) 50%. Adversary suggested 45%. I go slightly higher: the confidential S-1, the leaked prospectus and White House hostility are credible and folded into the world state, and an AI-bylined slowdown endorsement is exactly what IPO counsel resists.

Threat 2 ["Cartel lobbying" / partisan framing]: P(materialises) 40%. Adversary suggested 35%. I go slightly higher because Sacks has already run this precise argument. The Casar outreach adds a separate route that does not depend on publication. If the post is vetoed, only the milder Casar-optics version applies.

Threat 3 [Dual-use review guts toolkit]: P(materialises) 55%. Adversary suggested 40%. I go higher because pushing cyber-offence benchmarks and sandbox-escape harnesses directly to DeepSeek and Alibaba during an active remote-access export review would almost certainly be trimmed by legal and national-security review.

Threat 4 [Evaluator collusion / eval awareness]: P(materialises) 40%. Adversary suggested 35%. I go slightly higher because same-family evaluator blind spots and eval awareness are well documented in Claude-class models, and an honest internal red-team is likely to surface the confound early.

Threat 5 [Rival acceleration and investor pressure]: P(materialises) 45%. Adversary suggested 35%. I go higher because the threat is disjunctive: an OpenAI preview, a Gemini Deep Think tier, or a DeepSeek release already expected in December or January. The leadership compute-diversion part is the weaker link and will be resolved proportionally.
</threat_odds>
